TWST (TWST) Stock Analysis
Verdict: AVOID
Extreme technical extension and heavy insider selling signal a price-value disconnect despite strong 52% gross margins and revenue growth.
Investment score: 38/100
Twist Bioscience is currently trading in 'bubble' territory relative to its fundamentals and analyst targets. While the company's DNA synthesis technology is market-leading, the combination of persistent losses, aggressive insider selling at prices 12% lower than current levels, and a 22% single-day spike without a fundamental catalyst creates a high-risk entry point.
Peers
| Peer | P/E | P/B | P/S | EV/EBITDA | ROIC % | Net margin % |
|---|---|---|---|---|---|---|
| IONS | -17.57 | 22.87 | 11.56 | 2.81 | — | -0.65 |
| PTGX | 127.20 | 12.14 | 35.34 | 111.76 | — | 0.29 |
| SYRE | -55.86 | 8.38 | 104.52 | -50.10 | — | -1.98 |
| PCVX | -8.29 | 3.32 | 0.00 | -8.63 | — | 0.00 |
| IMVT | -15.94 | 12.57 | 1307.94 | -15.75 | — | -75.86 |